Allarity Therapeutics, Inc. has announced the postponement of its 2024 Annual Meeting of Stockholders, which was originally scheduled for July 26, 2024. The decision to delay the meeting was made by the company's board of directors on July 25, 2024, one day before the planned event. The board cited the company's bylaws as the basis for their authority to reschedule the meeting. A new date for the Annual Meeting has yet to be determined, but the board will establish this date and, if necessary, a new record date for stockholder voting eligibility. The company will issue a notice and, if applicable, an updated Proxy Statement to all eligible stockholders based on the original record date of June 14, 2024, or a new record date. This information was provided in a supplement to the Proxy Statement filed with the Securities and Exchange Commission on July 1, 2024. Allarity Therapeutics has urged stockholders to review the Proxy Statement and other relevant documents filed with the SEC for more information regarding the Annual Meeting and the matters to be voted on.

Allarity Therapeutics, Inc. has announced the postponement of its 2024 Annual Meeting of Stockholders, which was originally scheduled for July 26, 2024. The decision to delay the meeting was made by the company's board of directors on July 25, 2024, one day before the planned event. The board cited the company's bylaws as the basis for their authority to reschedule the meeting. A new date for the Annual Meeting has yet to be determined, but the board will establish this date and, if necessary, a new record date for stockholder voting eligibility. The company will issue a notice and, if applicable, an updated Proxy Statement to all eligible stockholders based on the original record date of June 14, 2024, or a new record date. This information was provided in a supplement to the Proxy Statement filed with the Securities and Exchange Commission on July 1, 2024. Allarity Therapeutics has urged stockholders to review the Proxy Statement and other relevant documents filed with the SEC for more information regarding the Annual Meeting and the matters to be voted on.